First Patient dosed and site in UK announced

PassageBio have announced that the first patient has been dosed in the GALax-C study of PBKR03 gene therapy for early infantile Krabbe disease.

Please click on the link to read the full announcement: https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Doses-First-Patient-in-Global-Clinical-Trial-for-Infantile-Krabbe-Disease-A-Rare-Fatal-Pediatric-Condition/default.aspx

 

The first patient was part of a global phase 1/2 trial. PassageBio have a site in the UK in Manchester University that is active but it is not yet recruiting.

To find out more information about the clinical trial, please click on the link: https://clinicaltrials.gov/ct2/show/NCT04771416?term=passage+bio&cond=krabbe+disease&draw=2&rank=1